Applied DNA Announces Receipt of International Patents on its Beacon® Secure Optical Molecular Marker Technologies
February 24 2020 - 9:00AM
Business Wire
New Patents in Key International Markets Allow
1st-Level Verification in Seconds
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
"Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing that brings integrity to global supply chains, and
innovation to diagnostics and nucleic-based therapeutics, today
announced the issuance of a Chinese patent and the receipt of a
Notice of Allowability for a Canadian patent application, both for
the invention “Encrypted Optical Markers for Security Applications”
relating to its Beacon encrypted optical molecular marker
technologies. The Company was previously granted United States
Patent No. 10,047,282 on its Beacon technologies and has additional
United States and international patent applications pending.
“China, Canada and the United States are key markets for our
Beacon technology which provides formidable brand protection and
assurance,” said Wayne Buchen, VP Strategic Sales. “The Company and
its partners utilizing the Beacon technology, such as global sewing
thread producer A&E, LLC and security label producer Schreiner
MediPharm, are seeing strong customer interest in areas such as
textiles, luxury goods and pharmaceutical packaging.”
The Beacon encrypted optical marker technology provides rapid,
secure, real-time in-field authentication of a DNA-tagged substrate
through the use of an encrypted fluorescing signal that can only be
identified in the presence of a specially formulated decryptant.
Without the paired decryptant, both Beacon and SigNature® DNA are
invisible to normal and UV light. Based on its novel technology, we
believe that Beacon is more secure than other non-encrypted
chemical tracers that can be purchased on the open market and
readily copied.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, our ability to successfully
enter into commercial contracts for the implementation of our
CertainT® platform, and various other factors detailed from time to
time in Applied DNA’s SEC reports and filings, including our Annual
Report on Form 10-K filed on December 12, 2019 and our subsequent
quarterly report on Form 10-Q filed on February 6, 2020, and other
reports we file with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200224005280/en/
Investor contact: Sanjay M. Hurry, 212-838-3777, LHA
Investor Relations, shurry@lhai.com Media Contact: John
Shearman, 631-240-8838, john.shearman@adnas.com Web:
www.adnas.com Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024